Comparison · NCT00991029-9dd8b596
Clopidogrel vs Placebo: Hemorrhagic Stroke
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Clopidogrel vs Placebo: Hemorrhagic Stroke. Trial comparisons, record NCT00991029-9dd8b596. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00991029-9dd8b596
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00206 | 0.000878 | 0.0048 | wilson | |
| Risk in group 2 | 0.00122 | 0.000417 | 0.0036 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000831 | -0.00182 | 0.0037 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.68 | 0.402 | 7.01 | log | |
| Odds ratio, group 1 over group 2 | 1.68 | 0.401 | 7.04 | log | |
| Number needed to treat, for one more participant with the outcome on Clopidogrel than on Placebo | 1,200 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Clopidogrel | Patients assigned to clopidogrel in addition to aspirin~Clopidogrel: Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days | 5 | 2,432 | OG000 |
| Group 2 | Placebo | Patients assigned to placebo in addition to aspirin~placebo: Loading dose of 8 tablets followed by one tablet daily for 89 days | 3 | 2,449 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Hemorrhagic Stroke
- Description
- Other safety outcome: Number of participants with Hemorrhagic stroke
- Time frame
- up to 90 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
- NCT number
- NCT00991029
- Phases
- PHASE3
- Conditions
- Ischemic Attack, Transient
- Interventions
- Clopidogrel, placebo
- Lead sponsor
- University of California, San Francisco
- Results first posted
- 2018-12-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00991029?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00991029-9dd8b596